India Backs Price Regulator In Ranbaxy Antibiotic Dispute
This article was originally published in PharmAsia News
India's government has backed its drug-price regulator's decision to fix the price of Ranbaxy Laboratories' Roscillin (ampicillin trihydrate IP) antibiotic. The action by the Chemicals and Fertilisers Ministry, which was ordered by the Delhi High Court to review Ranbaxy's objection, is considered a setback for Indian drug makers. The ministry's decision is seen as an indication the government has no intention of interfering with its National Pharmaceutical Pricing Authority. (Click here for more
You may also be interested in...
A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.
The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?